Eli Lilly and Company announced that patients with moderate-to-severe genital psoriasis treated with Taltz (ixekizumab) reported a greater decrease in...
H. Lundbeck A/S (Lundbeck) presented results about sexual functioning from a head-to-head study of Brintellix (vortioxetine) vs. escitalopram study in...
Flibanserin, an investigational, once-daily, non-hormonal pill for Hypoactive Sexual Desire Disorder in pre-menopausal women has adverse effects giving concern at...
AMAG Pharmaceuticals, Inc. announced that the FDA has approved Vyleesi (bremelanotide injection), a melanocortin receptor agonist, to treat acquired, generalized...
Systemic lupus erythematosus (SLE) is characterized by aberrant production of auto-antibodies and a sexual dimorphism both in the phenotypic expression and frequency of the disease between males and females.
Results from two Phase III studies of LibiGel (testosterone gel)from BioSante Pharmaceuticals, being BLOOM-1 and BLOOM-2 studies for Hypoactive Sexual...
Sprout Pharmaceuticals announced that it has received and appealed the FDA Complete Response Letter (CRL) for flibanserin through the Formal...
Testosterone deficiency (TD) is an increasingly common problem with significant health implications, but its diagnosis and management can be challenging.
H. Lundbeck A/S and its partner Takeda Pharmaceuticals USA, Inc., can once again expand the Clinical Trials section of the...
The FDA has on 30 July 2012 cleared the ingestible sensor IEM from Proteus Digital Health for marketing as a...